ReviewInternational journal of nanomedicine2025
Exosomes-Based Nanotherapeutic Strategies: An Important Approach for Spinal Cord Injury Repair.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MicroRNAs in Spinal Cord Injury: Molecular and Translational Insights.Brain and behavior · 2026Review
- Cell Therapy for Spinal Cord Injury: Mechanistic Insights and Translational Challenges.Cellular and molecular neurobiology · 2026Review
- Exosome-derived ncRNAs and proteins: inflammation regulatory mechanisms and biomarker potential in spinal cord injury.Frontiers in molecular biosciences · 2026Review
- Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Strategy for Spinal Cord Injury.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The repair and functional regeneration of spinal cord injury (SCI) remains a major challenge and focal point in regenerative medicine. Following SCI significant inflammation and neuronal damage occur. Conventional drug therapies often fail to precisely target the injured areas and cannot cross the blood-spinal cord barrier, severely limiting therapeutic efficacy. Therefore, precision therapeutics are crucial to improve the prognosis of SCI patients. In recent years, exosomes have gained widespread attention as natural delivery vehicles due to their low immunogenicity, high biocompatibility, and efficient delivery capabilities. Exosomes can effectively cross cell membranes and target specific cells, playing an important role in intercellular signaling. This makes them highly promising for precision therapies in SCI. By engineering exosomes for targeted delivery, new strategies can be developed for drug delivery, gene therapy, and personalized treatment after SCI. We aimed to review the biological functions of exosomes derived from different cell sources and discuss the role in tissue repair following SCI. Additionally, we explore the prospects and potential of exosomes in clinical SCI applications, to provide valuable research insights to improve functional recovery and long-term health management for SCI patients in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.